Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema*
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Objective To study the association of race and other patient characteristics associated with angiotensin converting enzyme (ACE) inhibitor-associated angioedema. Methods This was a retrospective cohort study of participants in the Tennessee Medicaid Program ( >or= 15 years of age) to whom ACE inhibitors had been prescribed from 1986 through 1992. Results We identified 82 patients with confirmed angioedema during 51,752 person-years of ACE inhibitor use, giving an overall rate of angioedema of 1.6 per 1000 person-years of ACE inhibitor use. After potential confounding factors were controlled for, the adjusted relative risk (RR) of angioedema among black American users of ACE inhibitors was 4.5 (95% confidence interval [CI] 2.9 to 6.8) compared with white subjects. In addition to race, other factors associated with a significantly increased relative risk in the entire population were the first 30 days of ACE inhibitor use (RR, 4.6; 95% CI, 2.5 to 8.5) compared to > 1 year of use, use of either lisinopril (RR, 2.2; 95% CI, 1.2 to 3.9) or enalapril (RR, 2.2; 95% CI, 1.4 to 3.5) compared to captopril, and previous hospitalization for any diagnosis within 30 days (RR, 2.0; 95% CI, 1.1 to 3.6). Neither ACE inhibitor dose nor concurrent diuretic use was associated with the risk of angioedema. Conclusions These data suggest that black Americans have a substantially increased risk of ACE inhibitor-associated angioedema compared with white subjects and that this increased risk cannot be…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Angiotensin I-converting enzyme inhibitors (ACEi) are widely used antihypertensive agents that are associated with a potentially life-threatening reaction, ACEi-angioedema.”
From A functional XPNPEP2 promoter haplotype leads to reduced plasma aminopeptidase P and increased risk of ACE inhibitor‐induced angioedema (2011) · cites this paper as Brown et al., 1996
In the citing paper
“Angioedema is a rare adverse effect of angiotensin converting enzyme (ACE) inhibitors that occurs more commonly in women and black Americans.”
From Sex-dependent and race-dependent association of XPNPEP2 C-2399A polymorphism with angiotensin-converting enzyme inhibitor-associated angioedema (2010) · cites this paper as [3]
In the citing paper
“This racial difference suggests that genetic factors modulate AE risk, but environmental factors are also important, because smokers taking ACEi have an increased susceptibility to AE (Coats 2002; Kostis et al. 2004).”
From A variant in XPNPEP2 is associated with angioedema induced by angiotensin I-converting enzyme inhibitors. (2005) · cites this paper as Brown et al. 1996
Citations
Cites
(2005) · Statistics for Biology and Health · doi:10.1007/0-387-27255-0_9 · Cited by 20,133
Materson, B. J., Reda, D. J., Cushman, W. C., Massie, B. M., Freis, E. D., Kochar, M. S., Hamburger, R. J., Fye, C., Lakshman, R., Gottdiener, J., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199304013281303 · Cited by 1,199
Israili, Z. H., & Hall, W. D. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-117-3-234 · Cited by 910
Clinical Profile of Angioedema Associated With Angiotensin Converting-Enzyme Inhibition
Slater, E. E. (1988) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1988.03410070095035 · Cited by 370
Levy, S. B., Lilley, J. J., Frigon, R. P., & Stone, R. A. (1977) · Journal of Clinical Investigation · doi:10.1172/jci108749 · Cited by 221
Prekallikrein Activation and High-Molecular-Weight Kininogen Consumption in Hereditary Angioedema
Schapira, M., Silver, L. D., Scott, C. F., Schmaier, A. H., Prograis, L. J., Curd, J. G., & Colman, R. W. (1983) · New England Journal of Medicine · doi:10.1056/nejm198305053081802 · Cited by 199
Angio-oedema and urticaria associated with angiotensin converting enzyme inhibitors.
Wood, S. M., Mann, R. D., & Rawlins, M. D. (1987) · BMJ · doi:10.1136/bmj.294.6564.91 · Cited by 120
Postmarketing surveillance of enalapril. I: Results of prescription-event monitoring.
Inman, W. H., Rawson, N. S., Wilton, L. V., Pearce, G. L., & Speirs, C. J. (1988) · BMJ · doi:10.1136/bmj.297.6652.826 · Cited by 112
Urinary Kallikrein and Plasma Renin Activity as Determinants of Renal Blood Flow
Levy, S. B., Lilley, J., Frigon, R. P., & Stone, R. A. (1977) · Cited by 73
Safety profiles of the angiotensin converting enzyme inhibitors captopril and enalapril
Irvin, J. D., & Viau, J. M. (1986) · The American Journal of Medicine · doi:10.1016/0002-9343(86)90945-9 · Cited by 72
Research works printed but not linked: 1
- Cameron H. A., 1989, J Hum Hypertens, 3, 177
Cited by
Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L., Jones, D. W., Materson, B. J., Oparil, S., Wright, J. T., et al. (2003) · Hypertension · doi:10.1161/01.hyp.0000107251.49515.c2 · Cited by 13,271
Oparil, S., Acelajado, M. C., Bakris, G. L., Berlowitz, D. R., Cífková, R., Dominiczak, A. F., Grassi, G., Jordan, J., Poulter, N. R., Rodgers, A., et al. (2018) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2018.14 · Cited by 1,167
Angiotensin-Converting Enzyme Inhibitors
Brown, N. J., & Vaughan, D. E. (1998) · Circulation · doi:10.1161/01.cir.97.14.1411 · Cited by 958
“inhibitor use, angioedema may occur years after the initiation of therapy.(160) Therefore, patients should be advised to recog-”
BackgroundSelf-citationCicardi, M., Aberer, W., Banerji, A., Bas, M., Bernstein, J. A., Bork, K., Caballero, T., Farkas, H., Grumach, A., Kaplan, A. P., et al. (2014) · Allergy · doi:10.1111/all.12380 · Cited by 666
Propensity Score Methods for Confounding Control in Nonexperimental Research
Brookhart, M. A., Wyss, R., Layton, J. B., & Stürmer, T. (2013) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.113.000359 · Cited by 588
“Furthermore, the risk of angioedema is known to vary across race and may be heterogeneous across other subgroups.(41) The PS approach allows us to estimate a population treatment effect without the need to”
Background
Metadata
- Authors
- Brown, N. J., Ray, W. A., Snowden, M., & Griffin, M. R.
- Affiliations
- Vanderbilt University (US)
- Corresponding author
- Brown, Nancy J.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 1996-07
- Volume
- 60
- Issue
- 1
- Pages
- 8-13
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2111856132
- Cited by
- 313
- References
- 15
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 10 · 2023: 11 · 2022: 7 · 2021: 10 · 2020: 10 · 2019: 12 · 2018: 18 · 2017: 18 · 2016: 19 · 2015: 7 · 2014: 9 · 2013: 17 · 2012: 15
- FWCI
- 5.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Pharmacology & Therapeutics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Food and Drug Administration (FD-U-000073)
- Topics
- Health Sciences › Medicine › Hematology › Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- ACE inhibitors, race, African Americans, racial disparities, lisinopril, enalapril, captopril, recent hospitalization, drug safety
- MeSH terms
- Adolescent, Adult, Aged, Angioedema, Angiotensin-Converting Enzyme Inhibitors, Black or African American, Female, Humans, Male, Middle Aged, Retrospective Studies, Risk Factors, Cohort Studies, Multivariate Analysis, Black People
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema*. https://app.cochat.ai/papers/10.1016/s0009-9236(96)90161-7
- The paper
- Brown, N. J., Ray, W. A., Snowden, M., & Griffin, M. R. (1996). Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema*. Clinical Pharmacology & Therapeutics. https://doi.org/10.1016/s0009-9236(96)90161-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.